Keyword: Ocrevus

Roche's first-half sales climbed 7% to $28.3 billion, their fastest clip in about three years, thanks to stepped-up performance from its newer drugs.

Biogen grew sales 9% in the second quarter, beating Street expectations, but analysts on the company's conference call were focused elsewhere.

England’s cost watchdogs aren’t going to pay for Roche's Ocrevus, the only approved PPMS therapy—that is, until it gets cheaper.

NICE is now endorsing Ocrevus for NHS coverage in relapsing-remitting MS and will deliver a decision on the primary progressive form soon.

A new study showed Ocrevus could reduce patients' immune responses to vaccines against tetanus, seasonal flu and pneumococcus.

Roche says it's in the midst of one of the most successful multiple sclerosis launches ever—and MS has had some doozies.

Biogen's Spinraza sales only increased modestly quarter-over-quarter, but there's still plenty of growth ahead, execs say.

Crowding in the MS field hasn’t stopped Roche's Ocrevus from making a splash. But that competition has made it tough to snag reimbursement in England.

The biosimilar sales threat is getting real for Roche this year, but a lower tax rate means profits will grow just the same.